Suppr超能文献

尸体肾移植围手术期的液体和药物治疗

Perioperative fluid and drug therapy during cadaver kidney transplantation.

作者信息

Dawidson I J, Ar'Rajab A

机构信息

University of Texas, Southwestern Medical Center, Dallas.

出版信息

Clin Transpl. 1992:267-84.

PMID:1306705
Abstract
  1. For all outcome measures associated with delayed onset of urine output and the need for posttransplant dialysis, the prognosis is poor. Low 1-year graft survival of 49% and patient mortality of 13% associated with delayed function make it exceedingly important to identify measures that induce immediate posttransplant kidney function. 2. Intraoperative blood volume expansion with albumin improves short- and long-term posttransplant function at every level of analysis, including earlier urine onset, larger urine volumes, improved kidney function, decreased incidence of delayed and no function, and greater graft and patient survival. 3. Aggressive intraoperative blood volume expansion during cadaver renal transplantation enables the safe use of intraoperative verapamil without inducing hypotensive complications. 4. Intraoperative verapamil improves the decreased renal blood flow associated with poor function as seen after organ procurement and cold ischemia. 5. Clinical studies confirm previous animal research demonstrating that verapamil and other calcium antagonists prevent CsA-induced deterioration of renal blood flow. 6. Several studies have demonstrated elevated CsA blood concentrations during concomitant treatment with verapamil and diltiazem but not with the dihydropyridine class of calcium antagonists. 7. Despite the higher CsA blood levels, kidney function, as determined by serum creatinine and glomerular filtration rate, improves with verapamil. 8. Verapamil given intraoperatively into the renal artery after revascularization improves renal function and reduces the need for posttransplant hemodialysis. 9. The combination of intraoperative verapamil and blood volume expansion acts synergistically, resulting in larger urine volumes, improved renal function, and decreased incidence of delayed function. 10. Most importantly, perioperative administration of albumin and verapamil independent of each other, significantly improves graft survival. 11. The beneficial effects of albumin are probably due to improved hemodynamics from increased blood and plasma volumes leading to better renal perfusion and prompt oxygenation. Secondly, blood volume expansion provides a safeguard against the intraoperative use of verapamil. The beneficial effects of verapamil on posttransplant outcome may be related to cellular protection from ischemia, selected vasodilation of the afferent arteriole, inherent immunosuppressive properties, and elevated CsA blood levels.
摘要
  1. 对于所有与少尿延迟发作及移植后透析需求相关的预后指标,预后情况均较差。移植肾功能延迟导致1年移植肾存活率低至49%,患者死亡率为13%,这使得确定能促使移植后肾功能立即恢复的措施极为重要。

  2. 术中用白蛋白扩容在各个分析层面均能改善移植后的短期和长期肾功能,包括更早出现尿液、尿量增多、肾功能改善、延迟和无功能发生率降低以及更高的移植肾存活率和患者存活率。

  3. 在尸体肾移植术中积极进行血容量扩充可安全使用术中维拉帕米,而不会引发低血压并发症。

  4. 术中维拉帕米可改善器官获取及冷缺血后因功能不良导致的肾血流量减少。

  5. 临床研究证实了先前的动物研究结果,即维拉帕米和其他钙拮抗剂可预防环孢素A(CsA)引起的肾血流量恶化。

  6. 多项研究表明,维拉帕米与地尔硫䓬联合治疗期间CsA血药浓度升高,但与二氢吡啶类钙拮抗剂联合治疗时则不然。

  7. 尽管CsA血药水平较高,但通过血清肌酐和肾小球滤过率测定的肾功能在使用维拉帕米后仍有所改善。

  8. 血管再通后术中经肾动脉给予维拉帕米可改善肾功能并减少移植后血液透析的需求。

  9. 术中维拉帕米与血容量扩充联合应用具有协同作用,可使尿量增多、肾功能改善、延迟功能发生率降低。

  10. 最重要的是,围手术期分别给予白蛋白和维拉帕米可显著提高移植肾存活率。

  11. 白蛋白的有益作用可能归因于血容量和血浆容量增加改善了血流动力学,从而导致更好的肾灌注和迅速的氧合作用。其次,血容量扩充为术中使用维拉帕米提供了保障。维拉帕米对移植后结局的有益作用可能与对缺血的细胞保护、入球小动脉的选择性血管舒张、固有的免疫抑制特性以及CsA血药水平升高有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验